<DOC>
	<DOCNO>NCT00495846</DOCNO>
	<brief_summary>The hepatocellular carcinoma ( HCC ) represent 5 % human malignancy , 500,000 death per year ( 1 ) . In Campania region , mortality HCC 2 time high rest Italy high locally prevalence hepatitis-C virus infection . Development HCC liver cirrhosis associate increase DNA synthesis regeneration hepatocytes ( 2 ) . Hepatocyte growth factor , transform growth factor-α , fibroblast growth factor well study ( 3,4 ) insulin-like growth factor system ( IGF-I , IGF-II binding protein ) less investigated . IGF-I IGF-II modulate growth , metabolism cell differentiation specific receptor liver ( 5 ) . IGF-I level upper normal range associate increase risk develop prostate cancer ( 6 ) , breast cancer ( 7 ) colon cancer ( 8 ) . Some data report increase expression IGF-II HCC ( 9,10 ) others suggest role increase IGF-I bioavailability HCC ( 11 ) . We report increased IGF-I/IGFBP-3 ratio patient HCC compare cirrhosis similar liver function , suggest increase IGF-I bioavailability HCC ( 12 ) . There currently medical treatment patient advance HCC poor prognosis ( survival &lt; 6 month ) . Because limited liver function , classical chemotherapy apply ( 13 ) . In patient HCC without cirrhosis , surgery possible 5 % cirrhosis first-line treatment still question survival &lt; 50 % three year operation . Patients suitable local resection HCC Child-Pugh 's `` hyper A '' liver function class , minority ( 14-16 ) . Percutaneous resection treatment may treat approximately 70 % -90 % tumor maximal diameter &lt; 3 cm ( 15,17-19 ) . Somatostatin analogue indicate patient neuroendocrine tumor express somatostatin receptor type 2 5 excellent safety profile . In advanced HCC , study demonstrate beneficial effect ( 20,21 ) others ( 22,23 ) . Only data available somatostatin receptor expression HCC ( 24,25 ) . Somatostatin analogue also clear-cut inhibitory effect circulate IGF-I level potential additional effect delay HCC progression .</brief_summary>
	<brief_title>GH , IGF-I Somatostatin Analogues Hepatocellular Carcinoma</brief_title>
	<detailed_description>Study objectives 1 . To evaluate relationship GH/IGF-I IGF-II axis development progression HCC ; 2 . To evaluate expression somatostatin receptor expression biopsy HCC quantitative RT-PCR immunohistochemistry vivo octreoscan ; 3 . To evaluate efficacy octreotide-LAR lanreotide-autogel compare placebo clinical symptom , liver function , biological marker tumor dimension ultrasonography advanced HCC patient ; 4 . To correlate response somatostatin analogue somatostatin receptor expression vitro vivo suppression IGF-I -II axis . Study design This pilot , open , prospective , monocentric study address : 1. patient liver cirrhosis multifocal HCC without portal vein invasion ; 2. patient liver cirrhosis single HCC nodule &gt; 6 cm size without portal vein invasion [ principal branch , right branch ( one segmentary arm ) , leave branch ( one segmentary arm ) ] ; 3. patient liver cirrhosis 3 HCC nodule &gt; 3 cm size without portal vein invasion [ principal branch , right branch ( one segmentary arm ) , leave branch ( one segmentary arm ) ] ; 4. patient cirrhosis without HCC . Study protocol All enrol subject subject baseline evaluation post-treatment evaluation accord treatment protocol ( see ) . A ) Clinical study vivo diagnostic routine analysis ( clinical evaluation , ECG , chest X-ray , blood chemistry , analysis liver function , α-FP assay , CEA , liver ultrasonography angio-ultrasonography , abdominal CT scan MRI ) ; blood sample GH , IGF-I , IGF-II , IGFBP-3 , ALS , insulin , IGFBP-1 IGFBP-2 ; whole body scintigraphy radiolabeled octreotide ( octreoscan ) liver biopsy patient good clinical condition accord good clinical practice procedure . Biopsy perform ultrasonography guidance 19G 21G needle local subcutaneous anesthesia ( lidocaine 2 % ) . Abdominal ultrasonography follow biopsy exclude hemorrage . The tissue sample store -80° analysis . B ) Morphological vitro study expression somatostatin receptor perform immunohistochemistry sequential section well RT-PCR use specific primer receptor ; study include analysis classical histology immunohistochemical marker . The study include positive negative control appropriate analysis result . Study duration The first study pilot study expect number patient fulfil inclusion criterion 15 address issue liver cirrhosis HCC . The enrollment period 12 month shorter 15 patient enrolled short time . The observational period expect 3-12 month , accord previous study . Treatment continue survivor even study end 12 month , accord previous study . Subsequently , study proceed placebo-controlled randomized study accord result obtain pilot study enroll 30-60 case patient HCC without cirrhosis 20-40 patient liver cirrhosis HCC . All patient register dedicated CRF data collect investigator involve data analysis . Withdrawal study The cause early study withdrawal record accord : 1. adverse event ; 2. treatment response patient ' clinical condition deterioration accord investigator judgment ; 3. major protocol violation ; 4. patient 's withdrawal consent . Concomitant therapy All patient continue treatment per investigator judgment . In case therapy withdrawn record CRF analyze potential beneficial effect somatostatin analogue therapy . Main outcome measure A ) Efficacy parameter For cirrhosis : Stabilization improvement live function parameter Reduction biological marker disease ( elevated start treatment ) Improvement quality life accord SF36 questionnaire For HCC : Prolongation survival curve ( &gt; 6 month ) Stabilization reduction tumor size Reduction disappearance portal vein thrombosis Stabilization improvement live function parameter Reduction biological marker disease ( elevated start treatment ) Improvement quality life accord SF36 questionnaire Expected result The expected result : 1 . Both cirrhotic normal liver express somatostatin receptor . The different receptor pattern suggest role receptor subtype HCC development . The correlation study also give insight role somatostatin receptor differentiation , stag prognosis HCC . 2 . Treatment somatostatin analogue prolong survival advance HCC patient . This occur accord liver function start treatment . We expect patient tumor high expression SS-2 receptor HCC long survival .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Patients cirrhosis without HCC liver function class already receive specific therapy cirrhosis accept subject liver biopsy sign write informed consent participate study Patients cirrhosis multifocal HCC clinical and/or radiological sign persistence recurrence HCC presence absence thrombosis portal vein , single nodule &gt; 6 cm size multiple nodule &gt; 3 cm size accept subject liver biopsy sign write informed consent participate study Age &lt; 18 yr &gt; 75 yrs Pregnancy lactation Intolerance somatostatin analogue Treatment protocol : In patient fulfil inclusion criterion , treatment begin octreotideLAR dose 30 mg every 28 day lanreotide autogel 120 mg every 28 day 3 month . After 28 , 56 74 day ( immediately next injection ) patient admit Day Hospital IX Division Internal Medicine D. Cotugno Hospital clinical examination , blood chemistry , blood sample IGF axis analysis , abdominal ultrasound . After 74 day , abdominal CT MRI also perform . Then , survivor interval injection reduce 21 day follow next 3 month do state day immediately precede injection . Then , subsequent followup interval injection reduce 14 day procedure repeat monthly interval . All patient fulfil inclusion criterion refuse participate study follow methodology receive somatostatin analogue treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>Somatostatin analogue</keyword>
	<keyword>Somatostatin receptor</keyword>
	<keyword>Octreotide</keyword>
	<keyword>Lanreotide</keyword>
	<keyword>IGF-I</keyword>
	<keyword>IGF-II</keyword>
</DOC>